Please sign in to follow a disease.
Pemphigus
MONDO:0006594Pemphigus is a group of rare autoimmune diseases that cause blistering of the skin and mucous membranes (mouth, nose, throat, eyes, and genitals).This conditioncan occur at any age, but often strikes people in middle or older age. Studies have shown that some populations may be at greater risk for certain types of pemphigus. For instance, people of Jewish descent and those from India, Southeast Europe, and the Middle East are at greater risk for pemphigus vulargis, while pemphigus foliaceus is more common in North America, Turkey, and South America. Pemphigus is a chronic disease which is best controlled by early diagnosis and treatment.Treatment includes steroids to reduce inflammation,drugs that suppress the immune system responseand antibiotics to treat associated infections. There are four main types of pemphigus: Pemphigus vulgaris Pemphigus foliaceus IgA pemphigus Paraneoplastic pemphigus
64 clinical trials for this condition and its sub-types, 20 tagged with Pemphigus itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →Sub-types of Pemphigus
-
Pemphigus vulgaris 13 trials
1 sub-type
- Pemphigus vegetans 0 trials
-
Pemphigus foliaceus 3 trials · 6 incl. sub-types
1 sub-type
- Pemphigus and fogo selvagem 3 trials
-
Hailey-Hailey disease 4 trials
-
Herpetiform pemphigus 0 trials
-
Pemphigoid gestationis 0 trials
-
Pemphigus erythematosus 0 trials
-
Can a targeted biologic outperform standard care for a rare blistering disease?
Disease control Not yet recruitingThis trial compares two treatment approaches for moderate to severe pemphigus vulgaris, a rare autoimmune disease causing painful blisters on skin and mucous membranes. One group receives rituximab (a biologic that targets immune B-cells) plus corticosteroids, while the other get…
Early phase 1 • Sponsor: Khyber Teaching Hospital • Aim: Disease control
Last updated Aug 20, 2026 00:00 UTC
-
Experimental CAR-T injection aims to tame autoimmune diseases
Disease control Not yet recruitingThis early-phase trial tests an injection called KSVCBD, a type of CAR-T cell therapy, in 60 adults with severe autoimmune diseases like lupus and scleroderma. The goal is to see if it's safe and to get a first look at whether it might help control the disease. Participants recei…
Early phase 1 • Sponsor: Chinese PLA General Hospital • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
Immune system reset: CAR T-Cells take on autoimmune diseases
Disease control Not yet recruitingThis study tests a new treatment using CD19 CAR T-cells for people with severe autoimmune diseases that haven't improved with standard therapies. About 30 participants will receive a single dose of these engineered immune cells after chemotherapy. The goal is to see if it's safe …
Phase 1/2 • Sponsor: Hebei Senlang Biotechnology Inc., Ltd. • Aim: Disease control
Last updated Jun 26, 2026 15:19 UTC